

Emerging Targets for the Diagnosis of Cancer

NTRK Fusion in Solid Tumors CME

THURSDAY, NOVEMBER 1, 2018

TIME: 7:30 PM – 8:30 PM

LOCATION: SAN ANTONIO, TX

VENUE: HENRY B. GONZÁLEZ CONVENTION CENTER

ROOM: 221

MODERATOR

Eric Q. Konnick, MD, MS

Assistant Professor

Associate Director - Genetics and Solid Tumor Lab

Director – Genetics Preatalytical Services

University of Washington Medical Center

Seattle, Washington



PANELISTS

Todd Bauer, MD

Associate Director

Drug Development

Principal Investigator

Sarah Cannon Research Institute

Tennessee Oncology, PLLC

Nashville, Tennessee



Dara L. Aisner, MD, PhD

Associate Professor

University of Colorado School of Medicine

Aurora, Colorado



How to obtain credit for this live event from your personal device

Attendees WITH a Medscape username and profile:

1. Log in to Medscape: www.medscape.org
2. Visit the CME certificate page by December 15, 2018:
www.medscape.org/symposium/molecular-pathology-ntrk-credit
3. Complete the online evaluation form
4. Print certificate online from the Medscape Activity Tracker

Attendees WITHOUT a Medscape username and profile:

1. Create a personal Medscape profile on www.medscape.org
2. Visit the CME certificate page by December 15, 2018:
www.medscape.org/symposium/molecular-pathology-ntrk-credit
3. Complete the online evaluation form
4. Print certificate online from the Medscape Activity Tracker

TO EARN YOUR CREDIT VISIT:

www.medscape.org/symposium/molecular-pathology-ntrk-credit

or Scan QR code below with your personal device

Valid through December 15, 2018



1. **Android users:** Open the QR reader on your device or download one from the Google Play Store
2. **Apple users:** Open the camera app or QR reader on your device
3. Align the camera with the QR code.
3. The phone will automatically scan the code. Or, press the camera button. Done!

Share your thoughts on *NTRK* fusion in solid tumors

@MedscapeCME #AMP2018

Supported by an independent
educational grant from Bayer and
Loxo Oncology.

Developed through a partnership between Medscape
and the Association for Molecular Pathology.



Medscape
Oncology

AGENDA

7:30 PM

Welcome and Introductions

Eric Q. Konnick MD, MS

7:35 PM

Biopsy and Initial Testing for NTRK

Dara L. Aisner, MD, PhD

7:50 PM

Clinical Management of NTRK Fusion-Positive Cancers

Todd Bauer, MD

8:00 PM

TRK TKI Resistance Mechanisms and Management of Disease Upon Progression

Eric Q. Konnick MD, MS

8:10 PM

Panel Discussion on Reporting Results

Panel

8:20 PM

Question and Answer Session

Panel

TARGET AUDIENCE

This activity is intended for pathologists and oncologists.

LEARNING OBJECTIVES

Upon completion of this activity, participants will:

Have increased knowledge regarding the

- Clinical trial data supporting treatment selection in patients with *NTRK* fusion-positive solid tumors

Have greater competence related to

- The most appropriate testing strategy for detection of *NTRK* fusions to allow accurate characterization of a patient's cancer
- Accurate reporting of biomarker test results to other members of the care team to help guide optimal treatment selection throughout the continuum of a patient's disease

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this live activity for a maximum of 1.0 **AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Medscape



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

DISCLOSURES

MODERATOR

Eric Q. Konnick, MD, MS

Eric Q. Konnick, MD, MS, has disclosed the following relevant financial relationships:

Served as a speaker or a member of a speakers bureau for: Ventana Medical Systems, NCCN

Dr Konnick does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Konnick does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

PANELISTS

Todd Bauer, MD

Todd Bauer, MD, has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Guardant Health; Ignyta; Loxo Oncology; Pfizer Inc.; Moderna Therapeutics

Received grants for clinical research from: AbbVie Inc.; Aileron Therapeutics; Amgen Inc.; Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Beijing Jacobio Pharmaceutical Co. Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Calithera Biosciences; Daiichi Sankyo, Inc.; Deciphera; Five Prime Therapeutics; Genentech, Inc.; GlaxoSmithKline; Ignyta; Immunocore; Immunogen; Incyte Corporation; Kolltan Pharmaceuticals; Leap Therapeutics; MabVax; MedImmune Inc.; Medpacto, Inc.; Merck & Co., Inc.; Merrimack; Millenium; Mirati Therapeutics; Moderna Therapeutics; Novartis Pharmaceuticals Corporation; Peloton Therapeutics, Inc.; Pfizer Inc.; Principia Biopharma; Roche; Sanofi; Stemline Therapeutics

Other: Fees paid to TMB / SCRI

Dr Bauer does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Bauer does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Dara L. Aisner, MD, PhD

Dara L. Aisner, MD, PhD, has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: AbbVie Inc.; Bayer HealthCare; Bristol-Myers Squibb Company; Genentech, Inc.

Received grants for clinical research from: Genentech, Inc.

Dr Aisner does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Aisner does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.